Amy Sanford, MD
Hematology & Oncology · Sioux Falls, SDNPI 1679708283
Payments from drug & device makers
What this record shows
3 manufacturers reported payments, led by Daiichi Sankyo Inc. at 57.2% of the total. That places this record below the midpoint for hematology & oncology clinicians in SD, where the typical reported total is $811.
Across 4 payments — averaging $13.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$31
- Gilead$12
- Epizyme, Inc.$12
Across 126 payments — averaging $6643.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$797K
- Eli Lilly$40K
What the payments were for
- Food & beverage$3157%
- Education$2343%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 2 | $31 |
| Gilead | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
How this compares
$55 in reported general payments places this provider in the 10th percentile of 28 hematology & oncology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| InlytaAxitinib | 19 | $381,463 |
| TagrissoOsimertinib Mesylate | 15 | $251,297 |
| Abiraterone Acetate | 38 | $80,322 |
| EliquisApixaban | 17 | $12,922 |
| Ondansetron OdtOndansetron | 48 | $736 |
| Prochlorperazine Maleate | 56 | $681 |
| Oxycodone Hcl | 27 | $642 |
| Omeprazole | 46 | $444 |
| Prednisone | 72 | $246 |
| Anastrozole | 12 | $195 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 14 | $145 |
| Famotidine | 19 | $136 |
| Levothyroxine Sodium | 14 | $54 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Sioux Falls
- Kelly McCaulSioux Falls$1.2M
- Roberto Ferro ValdesSioux Falls$142K
- Waqas JehangirSioux Falls$23K
- Steven PowellSioux Falls$13K
- Benjamin SolomonSioux Falls$5K
- Miroslaw MazurczakSioux Falls$2K
- Mark HuberSioux Falls$1K
- Ryan VacaSioux Falls$1K
- Michael McHaleSioux Falls$811
- Heidi McKeanSioux Falls$552
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.